(Reuters) – Novavax Inc said Monday that it has begun enrolling volunteers by the time of an ongoing clinical trial of its COVID-19 vaccine candidate, and provisional knowledge is expected by the fourth quarter of 2020.
In the new phase, age organization expanded, and adults over the age of 60 to 84 accounted for approximately 50% of the trial population.
Preliminary knowledge of a small clinical trial of the vaccine showed that it produced the highest levels of anti-virus antibodies, and the company intends to begin larger studies to off download regulatory approvals starting in December.
The candidate vaccine is one of nearly 30 that have been tested lately in international human clinical trials and lags behind AstraZeneca, Pfizer and Moderna applicants who are at a complex study level.
In July, the U. S. government will be able to do so. But it’s not the first time It awarded Novavax $1. 6 billion to verify and manufacture its vaccine in the United States, with the purpose of delivering one hundred million doses through January.
Britain has also partnered with the company to purchase 60 million doses of its candidate vaccine, some of which will be products manufactured by Fujifilm Diosynth Biotechnologies in Stockton-on-Tees in northern England.
The goal is to recruit up to 1,500 healthy volunteers at up to 40 sites in the United States and Australia, Novavax said.
Last week, the drug developer initiated a mid-term examination of his COVID-19 vaccine in South Africa.
Reporting through Ankur Banerjee and Vishwadha Chander in Bangalore; Edited through Arun Koyyur
All quotes were delayed for at least 15 minutes. See here for a complete list of operations and delays.
© 2020 Reuters. All rights reserved.